Learn more about
how donating
plasma works

Donation Process

Hear from the people who benefit from your donations

Patient Stories

At Grifols, our mission is to improve the health and well-being of people around the world

Grifols is a global healthcare company with more than 13,000 employees in 25 countries working together to improve people's health and well-being. We produce and market life-saving, plasma-derived medicines, diagnostic systems and hospital pharmacy products that are used to treat patients in more than 100 countries worldwide.

Grifols was founded in 1940 by Dr. José Antonio Grifols Lucas in Barcelona, Spain. Ever since, Grifols has been on the forefront of the plasma industry, pioneering many of the sophisticated techniques used today for the collection, testing and manufacturing of plasma-derived medicines. Over the years, we have created the world's largest network of plasma donation centers, making Grifols a world leader in plasma collection and a leading global producer of plasma-derived medicines.

Our commitment to serving people is central to everything we do. That's why we also seek to hire the very best employees and strive to create a dynamic, energetic organization. As a company, we take great pride in ensuring quality, integrity and safety in everything we do – it's at the core of who we are. After all, our products are of vital importance to the quality of life and health of the patients we serve.

Locate a plasma donation center

Learn about Grifols

Visit the online Grifols Museum

Grifols: A Retrospective History of Innovation

  • Grifols entered the U.S. plasma collection market in 2002 with the purchase of SeraCare, now named Biomat USA, Inc.
  • One year later, Grifols acquired the assets of Alpha Therapeutic Corporation-Mitsubishi, which included a plasma therapy manufacturing plant in Los Angeles.
  • Grifols became the second largest collector of human plasma in the world after acquiring PlasmaCare, Inc., a Cincinnati, Ohio-based plasma collection company in March 2006.
  • The FDA approved a prion-removal method for Grifols products.
  • The FDA approved the first liquid intravenous immune globulin (IGIV) for treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). This is the first IGIV approved to treat this disorder.
  • Grifols acquired Talecris Biotherapeutics Holdings Corp. in June 2011 and became the third-largest global manufacturer of plasma-derived protein therapies. The acquisition enlarged Grifols' plasma collection platform to approximately 150 donor centers across the U.S.
  • PediGri® was implemented, becoming the only program in the industry to offer a comprehensive quality and safety history of each product.
  • Grifols developed the first pasteurized liquid immune globulin in the world. Pasteurization is the most suitable method for eliminating possible pathogens.
  • Grifols incorporated HIV antibody testing of plasma months before it became compulsory.
  • The first double viral-inactivated Factor VIII concentrate in the world was developed. This was treated with solvent/detergent and heat in response to the threat of HIV
  • José Antonio Grífols Lucas became the first researcher to publish significant clinical data on the plasmapheresis technique used to separate plasma from blood and reinject the red blood cells back into the donor. The results of his work were presented at the Congress of the International Society of Blood Transfusion in Lisbon.
  • The plasmapheresis technique provided the means for large-scale plasma collection for manufacturing medicines.
  • Grifols obtained the Spanish patent for freeze-drying plasma and opened one of Europe's first private blood banks.